23andMe develops its own compound, and licenses it to a pharmaceutical company.
Date: 2020
The company uses their own genetic data to produce an antibody that "targets a family of proteins associated with several autoimmune and inflammatory diseases, including lupus and Crohn's disease" (Musil, 2020).
The Spanish pharmaceutical company, Almirall, is then licensed to develop and commercialize the antibody for worldwide use.